A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer

PURPOSE: Recurrent platinum-resistant ovarian cancer has no curative options, necessitating the development of novel treatments, including immunotherapy. RATIONALE: Patient-derived T cells can be genetically modified to express chimeric antigen receptors (CARs) specific to tumor-associated antigens...

Descripción completa

Detalles Bibliográficos
Autores principales: Koneru, Mythili, O’Cearbhaill, Roisin, Pendharkar, Swati, Spriggs, David R, Brentjens, Renier J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438636/
https://www.ncbi.nlm.nih.gov/pubmed/25890361
http://dx.doi.org/10.1186/s12967-015-0460-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438636/
https://www.ncbi.nlm.nih.gov/pubmed/25890361
http://dx.doi.org/10.1186/s12967-015-0460-x

Ejemplares similares